Pediatric Multisystem Inflammatory Syndrome Temporally associated with SARS-CoV-2, (PMIS-TS) represents the new unit, partially imitating the previously described Kawasaki disease. Due to variable and frequently incomplete clinical presentation together with variable disease severity, the real incidence in pediatric population remains unclear. Currently, PIMS-TS is defined by persistent fever, elevation of inflammatory markers, organ dysfunction (cardiac, central nervous system, respiratory, coagulation, renal, gastrointestinal), skin lesions (exanthematous), and absence of other possible etiology.
During the world COVID-19 pandemic (2020-2022), pediatric patients with PIMS-TS represented a significant part of pediatric intensive care unit (PICU) load. The initial clinical presentation of patients with PIMS-TS could vary significantly, and also due to progressively evolving recommendations, the diagnostic a therapy could vary regionally and over the time too. The aim of this retrospective cohort trial was to describe the initial clinical presentation, diagnostics, therapy and clinical outcome of pediatric patients admitted during 2020-2022 to the one of the 3 university hospital PICUs.
Study Type
OBSERVATIONAL
Enrollment
180
PIMS-TS diagnostic a treatment
Brno University Hospital
Brno, South Moravian, Czechia
Initial clinical presentation
Vital signs
Time frame: During the first 24 hours after PICU admission
Initial laboratory results
Time frame: During the first 24 hours after PICU admission
PIMS-TS treatment
PIMS-TS treatment specification
Time frame: During the first month after PICU admission
PIMS-TS outcome
clinical and cardiology outcome after 1 month
Time frame: after one month from hospital discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.